Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Maravai LifeSciences beat quarterly expectations, reporting a loss of $0.02 per share versus the $0.04 consensus estimate and revenue of $51.44 million versus $48.67 million expected. Revenue rose 9% year over year, driven by growth at TriLink and Cygnus.
• Profitability and financial flexibility improved significantly: adjusted gross margin expanded to 58.9%, adjusted EBITDA increased to $8.7 million, and debt maturities were extended to 2032. The company also raised full-year adjusted EBITDA guidance to $33 million-$35 million while maintaining revenue guidance of $205 million-$215 million.
• Despite the stronger outlook, Maravai remains unprofitable, with a negative net margin and return on equity. Analyst sentiment is mixed—the average rating is “Hold,” although Wells Fargo raised its price target to $6.50 and assigned an “Overweight” rating.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02, FiscalAI reports. The business had revenue of $51.44 million during the quarter, compared to analyst estimates of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.34% and a negative net margin of 37.07%.

Here are the key takeaways from Maravai LifeSciences' conference call:

• Q2 revenue grew 9% year over year to $51.4 million, led by 12% growth at TriLink, including a 55% increase in GMP consumables and 17% growth in discovery mRNA. Cygnus also delivered its fifth consecutive quarter of growth, with revenue up 3%.
• Profitability improved sharply, with adjusted gross margin expanding more than 1,600 basis points to 58.9% and adjusted EBITDA rising $19.1 million year over year to $8.7 million. Management attributed the improvement to higher revenue, favorable mix and cost restructuring.
• Maravai significantly strengthened its balance sheet by refinancing debt, ending the quarter with $147.1 million of debt and $70.1 million of cash, while extending maturities to 2032. Management said debt has been cut roughly in half since the start of 2026, improving financial flexibility.
• The company raised full-year adjusted EBITDA guidance to $33 million-$35 million and now expects gross-margin improvement of more than 1,400 basis points, while maintaining 2026 revenue guidance of $205 million-$215 million. Management cited strong demand but kept revenue guidance prudent because CDMO and large GMP orders are program-driven and can shift between quarters.
• Innovation and pipeline adoption continued to build: ModTail exceeded 125 customers one year after launch, GMP-grade ModTail is expected to launch later in 2026 with customer orders anticipated in 2027, and TriLink now has six GMP customers transitioning in 2026. Longer-term commercial-program growth is expected to become more meaningful around 2027-2029, but timing remains dependent on customers’ clinical progress.

Maravai LifeSciences Trading Down 0.3%

Shares of NASDAQ:MRVI traded down $0.02 on Friday, reaching $6.23. 4,077,168 shares of the company traded hands, compared to its average volume of 2,684,640. The stock has a market capitalization of $1.61 billion, a P/E ratio of -11.98 and a beta of 0.63. Maravai LifeSciences has a 52 week low of $2.03 and a 52 week high of $7.44. The business's 50-day simple moving average is $5.98 and its 200 day simple moving average is $4.38. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MRVI shares. Wells Fargo & Company lifted their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an "overweight" rating in a research note on Friday. Weiss Ratings raised shares of Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 29th. Wall Street Zen lowered shares of Maravai LifeSciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, UBS Group reiterated a "reduce" rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $5.83.

Insider Buying and Selling at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel owned 360,767 shares of the company's stock, valued at $1,825,481.02. This represents a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.49% of the company's stock.

Hedge Funds Weigh In On Maravai LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company's stock valued at $20,595,000 after purchasing an additional 178,445 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Maravai LifeSciences by 1.7% in the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company's stock worth $20,148,000 after acquiring an additional 104,355 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Maravai LifeSciences by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company's stock worth $9,259,000 after acquiring an additional 34,447 shares in the last quarter. State Street Corp grew its stake in Maravai LifeSciences by 1.1% in the fourth quarter. State Street Corp now owns 2,414,249 shares of the company's stock worth $7,846,000 after purchasing an additional 27,219 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Maravai LifeSciences in the fourth quarter worth $7,670,000. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences News Roundup

Here are the key news stories impacting Maravai LifeSciences this week:

• Positive Sentiment: Maravai reported second-quarter revenue of $51.44 million, exceeding analysts’ $48.67 million consensus estimate. The company also reported a quarterly loss per share of approximately $0.02, narrower than expectations of roughly $0.04-$0.05, according to the earnings coverage. Maravai LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo’s higher valuation target and “Overweight” rating indicate greater confidence in Maravai’s growth outlook and provide a near-term catalyst for the shares. Wells Fargo price target report
• Neutral Sentiment: Management issued fiscal 2026 revenue guidance of $205 million to $215 million, a range that broadly brackets the $210.4 million analyst consensus. The update offers limited surprise but provides visibility into the company’s expected performance. Maravai LifeSciences 2026 Q2 Results Presentation
• Negative Sentiment: Maravai remains unprofitable, with a negative net margin and negative return on equity. Continued quarterly losses could limit the stock’s upside unless revenue growth translates into improving profitability. Maravai LifeSciences Q2 earnings coverage

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source